RxDoctor Payments Data

Stephanie Gill, MD

Family Medicine · Wilkes Barre, PANPI 1174794564

Payments from drug & device makers

$439in general payments, 2019–2025

Across 22 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$93
  • GSK$57
  • Merck$46
  • Indivior Inc.$41
  • Amerisourcebergen Drug Corporation$32
  • Medtronic$32
  • plus $139 from 7 others

What the payments were for

  • Food & beverage$439100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk5$93
GSK3$57
Merck1$46
Indivior Inc.2$41
Amerisourcebergen Drug Corporation1$32
Medtronic2$32
AstraZeneca2$32
Pfizer1$21
Amgen1$21
Dexcom, Inc.1$18
Axsome Therapeutics, Inc.1$17
Shield Therapeutics Inc1$16
Braeburn Inc.1$16

How this compares

$439 in reported general payments places this provider in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,137
Medicare patients
33
Services billed
68

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$24,636
JardianceEmpagliflozin15$15,552
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,005
MounjaroTirzepatide14$12,984
Incruse ElliptaUmeclidinium Bromide12$4,376
ShingrixVaricella-Zoster Ge/As01b/Pf11$2,422
Carbamazepine ErCarbamazepine18$1,672
Levothyroxine Sodium112$1,494
Atorvastatin Calcium139$1,040
Ultra-Fine Original Pen NeedlePen Needle, Diabetic16$880
Albuterol Sulfate HfaAlbuterol Sulfate41$833
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen34$645
Ondansetron OdtOndansetron11$532
Lisinopril105$508
Carvedilol33$499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$24,63629 claims
GSKTrelegy Ellipta, Incruse Ellipta, Shingrix$57$19,80344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Wilkes Barre

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →